You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

91 search results for: expert insights

expert video

Most Burdensome Symptoms Rated by PN Patients

1 min

Dermatology

Dr. Chovatiya discusses the impact of pruritus on patients with PN.

expert video

The Risks of Associated Systemic and Atopic Comorbidities with AD

5 min

Dermatology

Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.

expert video

Association of Younger Age of Onset With Persistence of AD

1 min

Dermatology

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

1 min

Dermatology

Dr. Stephan Weidinger talks about the role of biomarkers and their impact on clinical decision-making.

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min

Dermatology

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min

Dermatology

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights the association between epidermal barrier dysfunction and S. aureus colonization in her talk at the ISDS 2023 ADVENT symposium.

expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.

expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

8 min

Pulmonology

Watch Prof G. Walter Canonica discuss the need to move beyond disease control to clinical remission in asthma and CRSwNP.

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

1 min

Dermatology

Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region